22405_Improving Outcomes of Patients With Transthyretin Amyloid Polyneuropathy (ATTR-PN)

In this program, ATTR-PN experts (chair Dr. Morie Gertz, and faculty members Dr. Amanda Peltier and Dr. Michelle Mauermann) will present, through lectures and “realworld” case studies, current evidence and best practices for management of ATTR-PN.

Transthyretin amyloid polyneuropathy (ATTR-PN) is often unrecognized, misdiagnosed and either treated inappropriately or undertreated owing to the rarity of the disease. There have been substantial advances in the understanding of ATTR-PN
which have led to enhanced diagnostic approaches with genetic testing, along with several recent targeted treatment approvals. Clinicians would benefit from a better understanding of the signs, symptoms, hereditability, and other factors that indicate possible ATTR-PN because organs like the heart, eyes, kidney and gastrointestinal system can be involved in addition to the peripheral and central nervous system. Clinicians also would benefit from expert guidance regarding the diagnostic process and a description of current treatment options for patients with ATTR-PN. In this program, ATTR-PN experts (chair Dr. Morie Gertz, and faculty members Dr. Amanda Peltier and Dr. Michelle Mauermann) will present, through lectures and “realworld” case studies, current evidence and best practices for management of ATTR-PN.

Login to your Account